Zydus Lifesciences is currently trading at RS. 907.55, up by 4.45 points or 0.49% from its previous closing of RS. 903.10 on the BSE.

The stock opened at RS. 930.60 and recorded a high of RS. 930.60 and a low of RS. 906.95. A total of 20,769 shares have been traded so far.

Zydus Lifesciences, a BSE group 'A' stock with a face value of RS. 1, reached a 52-week high of RS. 1323.90 on August 9, 2024, and a 52-week low of RS. 859.15 on March 4, 2025. Over the past week, the stock’s high and low were RS. 930.60 and RS. 880.00, respectively. The company's current market capitalization stands at RS. 90,872.99 crore.

The company's shareholding includes 74.98% held by promoters, 18.18% by institutions, and 6.84% by non-institutions.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg). Apalutamide is an androgen receptor inhibitor used for treating metastatic castration-sensitive prostate cancer. The tablets will be produced at Zydus Lifesciences Ltd (SEZ) in Ahmedabad.

Apalutamide tablets had annual sales of $1,099.8 million in the United States, as per IQVIA MAT January 2025 data. With this, the company now has 420 USFDA approvals and has filed 483 Abbreviated New Drug Applications (ANDAs) since FY 2003-04.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged in research, development, production, marketing, and distribution of pharmaceutical products across the value chain.